       Document 0500
 DOCN  M9620500
 TI    A pilot study to evaluate the development of resistance to nevirapine in
       asymptomatic human immunodeficiency virus-infected patients with CD4
       cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208.
 DT    9602
 AU    Havlir D; McLaughlin MM; Richman DD; Department of Medicine, University
       of California, San Diego, La; Jolla, USA.
 SO    J Infect Dis. 1995 Nov;172(5):1379-83. Unique Identifier : AIDSLINE
       MED/96036403
 AB    Treatment of human immunodeficiency virus (HIV) infection with
       nevirapine in patients with < 400 CD4 cells/mm3 rapidly selects for
       virus with reduced susceptibility to nevirapine. To test whether
       resistance would develop less quickly in patients with a lower virus
       burden, nevirapine was studied in asymptomatic patients with > 500 CD4
       cells/mm3. With 400 mg of nevirapine daily, the median reduction in HIV
       RNA was 0.51 log10 copies/mL, and all isolates recovered by 12 weeks
       were resistant to nevirapine. As in patients with lower CD4 cell counts,
       some patients experienced sustained reduction in plasma HIV RNA despite
       the presence of resistant virus. These results suggest that lower levels
       of HIV RNA and immunosuppression did not retard the rate of emergence of
       nevirapine-resistant virus; also, a polymerase chain reaction-based HIV
       RNA assay is sufficiently sensitive to evaluate the antiviral effect of
       a drug in patients with > 500 CD4 cells/mm3.
 DE    Antiviral Agents/*THERAPEUTIC USE  Clinical Trials  *CD4 Lymphocyte
       Count  Drug Resistance, Microbial  Female  Human  HIV/ISOLATION & PURIF
       HIV Seropositivity/*DRUG THERAPY/*IMMUNOLOGY  Immunosuppression  Male
       Pilot Projects  Polymerase Chain Reaction/METHODS
       Pyridines/*THERAPEUTIC USE  Regression Analysis  RNA, Viral/ANALYSIS
       Support, Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.  Time Factors
       CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

